Literature DB >> 18829338

Survival after resection of synchronous bilateral lung cancer.

Paul De Leyn1, Johnny Moons, Johan Vansteenkiste, Eric Verbeken, Dirk Van Raemdonck, Philippe Nafteux, Herbert Decaluwe, Tony Lerut.   

Abstract

OBJECTIVE: Due to recent advances in imaging, the incidence of patients presenting with bilateral lung lesions is increasing. A single contralateral lung lesion can be an isolated metastasis or a synchronous second primary lung cancer. For the revision of the TNM in 2009, the International Association for the Study of Lung Cancer Staging Committee proposes that patients with contralateral lung nodules remain classified as M1 disease. In this retrospective study, the survival after resection of synchronous bilateral lung cancer is evaluated.
METHODS: From our database of bronchial carcinoma, all patients with bilateral synchronous lung lesions between 1990 and 2007 were retrieved. We analysed 57 patients in which, after functional assessment and thorough staging, the decision was taken to treat the disease with bilateral resection. All these files were retrospectively reviewed. Twenty-one patients were excluded from this analysis because only one side was resected (n=15) or one of the lesions was non-neoplastic on final pathology (n=6).
RESULTS: Thirty-six patients underwent bilateral resection for synchronous multiple primary lung cancer. All resections were performed as sequential procedures. In 23 patients, one side was anatomically resected (2 pneumonectomies) and the contralateral side was resected by limited resection. In 10 patients a bilateral lobectomy was performed, and 3 patients had bilateral limited resections. Postoperative mortality was 2.8%. Eighteen patients had a tumour with a different histological pattern, confirmed by comparing both specimens by an experienced senior pathologist. The median survival after resection of synchronous bilateral lung cancer in our series was 25.4 months with a 5-year survival rate of 38%. There was no significant difference in survival between patients with different versus same histology. This survival is much higher compared to the survival of assumed stage IV disease.
CONCLUSIONS: Our study shows that selected patients with bilateral lung cancer may benefit from an aggressive approach, with acceptable morbidity and mortality, and rewarding long-term survival. Patients with a single contralateral lung lesion should not be treated as disseminated disease (stage IV). After extensive searching for metastatic spread, bilateral surgical resection should be considered in fit patients.

Entities:  

Mesh:

Year:  2008        PMID: 18829338     DOI: 10.1016/j.ejcts.2008.07.069

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  28 in total

1.  Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer.

Authors:  Zachary S Morris; Donald M Cannon; Brett A Morris; Søren M Bentzen; Kevin R Kozak
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

Review 2.  Non-intubated video-assisted thoracoscopic surgery anatomical resections: a new perspective for treatment of lung cancer.

Authors:  Jun Liu; Fei Cui; Jianxing He
Journal:  Ann Transl Med       Date:  2015-05

3.  Clinical features of multiple lung cancers based on thin-section computed tomography: what are the appropriate surgical strategies for second lung cancers?

Authors:  Aritoshi Hattori; Kenji Suzuki; Kazuya Takamochi; Shiaki Oh
Journal:  Surg Today       Date:  2014-05-22       Impact factor: 2.549

Review 4.  Surgical management of advanced non-small cell lung cancer.

Authors:  Gonzalo Varela; Pascal Alexandre Thomas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

5.  Surgical treatment of stage IV non-small cell lung cancer.

Authors:  Daigo Kawano; Sadanori Takeo; Masakazu Katsura; Shuichi Tsukamoto; Eri Masuyama; Yu Nakaji
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-30

6.  Management of Multifocal Lung Cancer: Results of a Survey.

Authors:  Konstantinos Leventakos; Tobias Peikert; David E Midthun; Julian R Molina; Shanda Blackmon; Francis C Nichols; Yolanda I Garces; Christopher L Hallemeier; Stephen J Murphy; George Vasmatzis; Sarah L Kratz; William P Holland; Charles F Thomas; John J Mullon; K Robert Shen; Stephen D Cassivi; Randolph S Marks; Marie Christine Aubry; Alex A Adjei; Ping Yang; Mark S Allen; Eric S Edell; Dennis Wigle; Aaron S Mansfield
Journal:  J Thorac Oncol       Date:  2017-06-03       Impact factor: 15.609

7.  Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases.

Authors:  Zhe Wang; Shu-Geng Gao; Qi Xue; Xiao-Tong Guo; Li-Xu Wang; Xin Yu; Yi-Kun Yang; Ju-Wei Mu
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 8.  Risk factors and management of oligometastatic non-small cell lung cancer.

Authors:  Akshar N Patel; Charles B Simone; Salma K Jabbour
Journal:  Ther Adv Respir Dis       Date:  2016-04-08       Impact factor: 4.031

9.  Patient, tumor, and healthcare factors associated with regional variability in lung cancer survival: a Spanish high-resolution population-based study.

Authors:  M Rodríguez-Barranco; E Salamanca-Fernández; M L Fajardo; E Bayo; Y-L Chang-Chan; J Expósito; C García; J Tallón; P Minicozzi; M Sant; D Petrova; M A Luque-Fernandez; M-J Sánchez
Journal:  Clin Transl Oncol       Date:  2018-10-19       Impact factor: 3.405

10.  Double primary non-small cell lung cancer with synchronous small cell lung cancer N2 nodes: a case report.

Authors:  Apostolos S Gogakos; Dimitrios Paliouras; Thomas Rallis; Fotios Chatzinikolaou; Persefoni Xirou; Katerina Tsirgogianni; Drosos Tsavlis; Nikos Sachpekidis; Kosmas Tsakiridis; Andreas Mpakas; Konstantinos Zarogoulidis; Athanasios Zissimopoulos; Paul Zarogoulidis; Nikolaos Barbetakis
Journal:  Ann Transl Med       Date:  2015-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.